New publications
Preparations
Antimicrobial drug from the group of fluoroquinolones - Tariwid - is a derivative of naphthydrine, with the active ingredient ofloxacin.
Indications of the tarivid
Antibacterial agent Tarihid is used to treat patients with infectious diseases caused by microorganisms that exhibit sensitivity to the action of ofloxacin.
It is appropriate to apply Tariwid in such diseases:
- various forms of the course of infectious pathologies of the respiratory system, including pneumonia and bronchial inflammation caused by the bacterium Haemophilus influenzae, as well as pathogens such as Escherichia coli, Proteus, Enterobacterium, Staphylococcus aureus, Legionella, Klebsiella;
- various forms of otolaryngological pathologies caused by staphylococcal and pseudomonas flora (exception - tonsillar angina);
- infectious pathologies of skin, musculoskeletal system caused by sensitive flora;
- abdominal infectious pathologies.
It is allowed to use Tarium to prevent the development of infectious complications in persons with weakened immunity (for example, with neutropenia).
Given the range of antimicrobial activity, it is not recommended to practice Tariwid's appointment in pathologies triggered by pneumococci and β-hemolytic streptococci.
Release form
Antibiotic Tarium is a tablet preparation in a film coat, with the main ingredient of ofloxacin.
Tablets of a white-yellowish hue, elongated, convex on both sides, with a dosing line and an inscription M on one side surface and XI on the other.
The drug is packed in 10 tablets in a cell box. The overall packaging is made of cardboard.
Pharmacodynamics
The bactericide Tariwid contains ofloxacin, an antibacterial ingredient belonging to the second generation of the fluoroquinolone series.
Tarivid has a wide range of antimicrobial activity: the action of the drug is due to inhibition of DNA-gyrase with a further disorder of reduplication of microbial DNA.
Tarium acts on strains of Staphylococcus aureus (also on variants resistant to methicillin), Neusherium, Citrobacterium, Enterobacterium, Escherichia, Klebsiella, Nafnium, Campylobacter, Chlamydia, Shigella, Proteus, etc.
There are known strains recognized as moderately sensitive to the drug Tarivid. These include, among other things, tuberculosis mycobacteria.
There is no sensitivity to tariwid in such microorganisms as strains of nocardia, ureaplasmas, and also in anaerobic bacteria. Tarium is ineffective in relation to pale treponema.
Pharmacokinetics
Absorption Tarivid in the digestive system is almost complete. Limit content in the plasma is detected one hour after the use of the drug.
Biological availability is equivalent to 100%.
The binding with plasma albumins is 25%.
A single use of Tariwid leads to the appearance of a limiting concentration of 2.5 to 3 mg per ml. The distribution volume is 120 liters.
During the course of Tariwid therapy, plasma levels do not change. The half-life can be from six to seven hours.
Approximately 5% of the consumed amount of Tarivid undergoes metabolic changes. About 90% leaves the body in unchanged form.
Contraindications
Do not practice therapy.
- hypersensitivity to drugs fluoroquinolone group;
- with lactose intolerance;
- with epilepsy;
- in the presence of complications caused by an earlier intake of fluoroquinolones.
Do not use Tariqid for the treatment of children under 18 years of age, as well as pregnant and lactating women.
Relative contraindications are:
- vascular atherosclerotic changes;
- impaired cerebral circulation;
- chronic form of failure of renal function;
- organic pathology of the central nervous system;
- extended interval QT.
Side effects of the tarivid
During the reception of Tariqid, various undesirable manifestations may occur:
- pain in the stomach and throughout the abdomen;
- disorders of defecation;
- nausea, worsening of appetite;
- inflammatory processes in the intestine;
- sleep disorders, overexcitation;
- pain in the head, dizziness, hallucinations;
- anxiety, restlessness;
- depression, impaired motor function, convulsions;
- extrapyramidal disorders;
- increased heart rate, hypotension;
- pain in the joints, tendonitis, muscle pain, myasthenia gravis;
- Cholestatic jaundice, hepatitis;
- exacerbation of kidney failure or nephritis;
- thrombocytopenia, agranulocytosis, anemia;
- deterioration of the hematopoietic function.
Allergic reaction can be expressed by itching, rashes, conjunctivitis, allergic rhinitis.
If the patient suffers from diabetes, then the use of Tariwid can cause him hypoglycemia.
If there are side effects on the background of Tarivid therapy, it is necessary to inform the doctor about it, as some undesirable symptoms can become an excuse for stopping the drug immediately.
Dosing and administration
Typically, tariver is taken orally, at the same time intervals. The drug may be taken with food, or before meals.
The necessary amount of Tarium is determined, taking into account the severity of infectious pathology, the ability of the kidneys to work, the resistance of microbes and the general state of human health.
Patients with normal renal function are recommended to treat 200 mg of Tariwith at intervals of 12 hours. The daily amount of the drug is 400 mg on average. If necessary, 400 mg per day may be taken at a time (preferably - shortly before sleep).
In cases where the patient is prescribed a daily amount of the drug, exceeding 400 mg, then it must be taken in two steps.
If the patient has a serious infectious pathology, or is painfully obese, then an increase in the daily amount of Tariwid (600 mg and above) is possible.
The maximum possible daily amount of the drug is 800 mg.
If the patient has disorders of renal function, dosage adjustment may be required:
- if the creatinine clearance is less than 50 ml per minute, then it is appropriate to treat 100-200 mg Tariwid once a day;
- if the creatinine clearance is less than 20 ml per minute, it is appropriate to treat 100 mg Tariwid once a day (alternatively 200 mg Tariwid once every two days, at the same time).
With insufficient liver function, it is contraindicated to use more than 400 mg of Tarivid daily.
As a rule, the therapeutic course continues until the clinical symptoms of infectious lesions are eliminated + 2-3 days.
During the entire treatment course, it is recommended to beware of the effects of ultraviolet rays.
Overdose
Taking high doses Tarihid can lead to dizziness, oppression of consciousness, disorientation, drowsiness, and vomiting.
If there is a suspicion of an overdose of Tarivid, you should rinse the stomach in a short time, take a sorbent drug. If there is a need, prescribe treatment depending on the detected pathological symptoms.
Special drugs with the properties of the antidote are not found.
Interactions with other drugs
Anti-acid agents based on aluminum, magnesium, zinc or iron impair the absorption of Tarivid. If the intake of such medications is unavoidable, it is important to withstand 2 hours of the interval between the use of Tarivid and anti-acid agents.
If simultaneous treatment with antagonists of vitamin K is carried out, then the quality of blood coagulation should be regularly monitored.
There may be an increase in the level of ofloxacin with simultaneous treatment of Tariwid with methotrexate, furosemide, cimetidine.
It is undesirable to take Tarivid in combination with non-steroidal anti-inflammatory drugs and theophylline, as this may increase the likelihood of developing convulsive seizures.
Neurotoxic effect can be observed after taking Tarivid against a background of non-steroidal anti-inflammatory drugs, preparations based on nitroimidazole.
Do not combine tariwid and glucocorticosteroids, as this increases the risk of damage to the tendons.
Because of the danger of increasing the QT interval, Tariwid should not be combined with antiarrhythmic drugs, macrolide antibiotics, antidepressants.
Because of the danger of kidney damage, it is undesirable to combine Tariwid with citrates, carbonic anhydrase inhibitors, sodium bicarbonate.
Attention!
To simplify the perception of information, this instruction for use of the drug "Tarif" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.